Heather J. Whitaker, Naoma Willam, Simon Cottrell, Rosalind Goudie, Nick Andrews, Josie Evans, Catherine Moore, Utkarsh Agrawal, Katie Hassell, Rory Gunson, Jana Zitha, Sneha Anand, Praveen Sebastian-Pillai, Panoraia Kalapotharakou, Cecilia Okusi, Katja Hoschler, Gavin Jamie, Beatrix Kele, Mark Hamilton, Anastasia Couzens, Catherine Quinot, Kathleen Pheasant, Rachel Byford, Kimberly Marsh, Chris Robertson, Simon de Lusignan, Christopher Williams, Maria Zambon, Jim McMenamin, Conall H. Watson
{"title":"英国 2022/23 季度末初级保健中流感疫苗的有效性。","authors":"Heather J. Whitaker, Naoma Willam, Simon Cottrell, Rosalind Goudie, Nick Andrews, Josie Evans, Catherine Moore, Utkarsh Agrawal, Katie Hassell, Rory Gunson, Jana Zitha, Sneha Anand, Praveen Sebastian-Pillai, Panoraia Kalapotharakou, Cecilia Okusi, Katja Hoschler, Gavin Jamie, Beatrix Kele, Mark Hamilton, Anastasia Couzens, Catherine Quinot, Kathleen Pheasant, Rachel Byford, Kimberly Marsh, Chris Robertson, Simon de Lusignan, Christopher Williams, Maria Zambon, Jim McMenamin, Conall H. Watson","doi":"10.1111/irv.13295","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The 2022/23 influenza season in the United Kingdom saw the return of influenza to prepandemic levels following two seasons with low influenza activity. The early season was dominated by A(H3N2), with cocirculation of A(H1N1), reaching a peak late December 2022, while influenza B circulated at low levels during the latter part of the season. From September to March 2022/23, influenza vaccines were offered, free of charge, to all aged 2–13 (and 14–15 in Scotland and Wales), adults up to 49 years of age with clinical risk conditions and adults aged 50 and above across the mainland United Kingdom.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>End-of-season adjusted vaccine effectiveness (VE) estimates against sentinel primary-care attendance for influenza-like illness, where influenza infection was laboratory confirmed, were calculated using the test negative design, adjusting for potential confounders.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Results In the mainland United Kingdom, end-of-season VE against all laboratory-confirmed influenza for all those > 65 years of age, most of whom received adjuvanted quadrivalent vaccines, was 30% (95% CI: −6% to 54%). VE for those aged 18–64, who largely received cell-based vaccines, was 47% (95% CI: 37%–56%). Overall VE for 2–17 year olds, predominantly receiving live attenuated vaccines, was 66% (95% CI: 53%–76%).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The paper provides evidence of moderate influenza VE in 2022/23.</p>\n </section>\n </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 5","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.13295","citationCount":"0","resultStr":"{\"title\":\"End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain\",\"authors\":\"Heather J. Whitaker, Naoma Willam, Simon Cottrell, Rosalind Goudie, Nick Andrews, Josie Evans, Catherine Moore, Utkarsh Agrawal, Katie Hassell, Rory Gunson, Jana Zitha, Sneha Anand, Praveen Sebastian-Pillai, Panoraia Kalapotharakou, Cecilia Okusi, Katja Hoschler, Gavin Jamie, Beatrix Kele, Mark Hamilton, Anastasia Couzens, Catherine Quinot, Kathleen Pheasant, Rachel Byford, Kimberly Marsh, Chris Robertson, Simon de Lusignan, Christopher Williams, Maria Zambon, Jim McMenamin, Conall H. Watson\",\"doi\":\"10.1111/irv.13295\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>The 2022/23 influenza season in the United Kingdom saw the return of influenza to prepandemic levels following two seasons with low influenza activity. The early season was dominated by A(H3N2), with cocirculation of A(H1N1), reaching a peak late December 2022, while influenza B circulated at low levels during the latter part of the season. From September to March 2022/23, influenza vaccines were offered, free of charge, to all aged 2–13 (and 14–15 in Scotland and Wales), adults up to 49 years of age with clinical risk conditions and adults aged 50 and above across the mainland United Kingdom.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>End-of-season adjusted vaccine effectiveness (VE) estimates against sentinel primary-care attendance for influenza-like illness, where influenza infection was laboratory confirmed, were calculated using the test negative design, adjusting for potential confounders.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Results In the mainland United Kingdom, end-of-season VE against all laboratory-confirmed influenza for all those > 65 years of age, most of whom received adjuvanted quadrivalent vaccines, was 30% (95% CI: −6% to 54%). VE for those aged 18–64, who largely received cell-based vaccines, was 47% (95% CI: 37%–56%). Overall VE for 2–17 year olds, predominantly receiving live attenuated vaccines, was 66% (95% CI: 53%–76%).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>The paper provides evidence of moderate influenza VE in 2022/23.</p>\\n </section>\\n </div>\",\"PeriodicalId\":13544,\"journal\":{\"name\":\"Influenza and Other Respiratory Viruses\",\"volume\":\"18 5\",\"pages\":\"\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-05-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.13295\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Influenza and Other Respiratory Viruses\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/irv.13295\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.13295","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain
Background
The 2022/23 influenza season in the United Kingdom saw the return of influenza to prepandemic levels following two seasons with low influenza activity. The early season was dominated by A(H3N2), with cocirculation of A(H1N1), reaching a peak late December 2022, while influenza B circulated at low levels during the latter part of the season. From September to March 2022/23, influenza vaccines were offered, free of charge, to all aged 2–13 (and 14–15 in Scotland and Wales), adults up to 49 years of age with clinical risk conditions and adults aged 50 and above across the mainland United Kingdom.
Methods
End-of-season adjusted vaccine effectiveness (VE) estimates against sentinel primary-care attendance for influenza-like illness, where influenza infection was laboratory confirmed, were calculated using the test negative design, adjusting for potential confounders.
Methods
Results In the mainland United Kingdom, end-of-season VE against all laboratory-confirmed influenza for all those > 65 years of age, most of whom received adjuvanted quadrivalent vaccines, was 30% (95% CI: −6% to 54%). VE for those aged 18–64, who largely received cell-based vaccines, was 47% (95% CI: 37%–56%). Overall VE for 2–17 year olds, predominantly receiving live attenuated vaccines, was 66% (95% CI: 53%–76%).
Conclusion
The paper provides evidence of moderate influenza VE in 2022/23.
期刊介绍：
Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases.
Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
